BIRT-1696-BS

BIRT-1696-BS is a small molecule drug that was initially developed by Boehringer Ingelheim International GmbH. It has undergone Phase 1 clinical trials to assess its safety, pharmacokinetics, and pharmacodynamics in healthy human subjects. The available studies involved single rising oral doses of the compound administered as a solution in PEG 400, with additional investigations into the effects of grapefruit juice and high-fat meals on its pharmacokinetics. As of the latest updates, there is no publicly available information regarding its mechanism of action, therapeutic targets, or specific indications beyond these early-phase studies[1][2][3][7]. The development status remains pending with no evidence of regulatory approval or active development for any particular disease.